Saltar al contenido
Merck
Todas las fotos(1)

Documentos

Y0001295

Spironolactone for system suitability

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

Spironolactone, 4-Pregnen-21-oic acid-17α-ol-3-one-7α-thiol γ-lactone 7-acetate, 7α-(Acetylthio)-17α-hydroxy-3-oxopregn-4-ene-21-carboxylic acid γ-lactone

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C24H32O4S
Número de CAS:
52-01-7
Peso molecular:
416.57
MDL number:
MFCD00082250
UNSPSC Code:
41116107
PubChem Substance ID:
329831347
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

spironolactone

manufacturer/tradename

EDQM

mp

207-208 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]45CCC(=O)O5)[C@H]13

InChI

1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1

InChI key

LXMSZDCAJNLERA-ZHYRCANASA-N

Gene Information

human ... NR3C2(4306)

¿Está buscando productos similares? Visita Guía de comparación de productos

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Spironolactone for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Spironolactone is a competitive aldosterone receptor antagonist. Used as potassium sparing diuretic.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Referencia del producto
Descripción
Precios

S1200000

Spironolactone, European Pharmacopoeia (EP) Reference Standard

1619006

Spironolactone, United States Pharmacopeia (USP) Reference Standard

1619017

Spironolactone Related Compound A, United States Pharmacopeia (USP) Reference Standard

BP306

Spironolactone, British Pharmacopoeia (BP) Reference Standard

PHR2886

Spironolactone, pharmaceutical secondary standard, certified reference material

PHR2887

Spironolactone Related Compound A, pharmaceutical secondary standard, certified reference material

PHR3135

Spironolactone Related Compound C, pharmaceutical secondary standard, certified reference material

pictograms

Health hazard
GHS08

signalword

Danger

Hazard Classifications

Carc. 2 - Repr. 1B - STOT RE 2

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

Lo sentimos, en este momento no disponemos de COAs para este producto en línea.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Well tolerated spironolactone-related hyponatremia.
Joel Handler
Journal of clinical hypertension (Greenwich, Conn.), 10(4), 317-321 (2008-04-11)
Spironolactone: an old friend rediscovered.
Domenic A Sica
Journal of clinical hypertension (Greenwich, Conn.), 8(7), 467-469 (2006-07-20)
Enrico Vizzardi et al.
The American journal of the medical sciences, 347(4), 271-276 (2013-11-08)
The purpose of this study is to evaluate long-term effects of spironolactone, an affordable and widely used aldosterone receptor blocker, in patients with heart failure (HF) and mild or no symptoms. The study is a single-blind, placebo-controlled, blinded endpoint, randomized
Doson Chua et al.
Clinical cardiology, 33(10), 604-608 (2010-10-21)
Spironolactone is used in the treatment of cardiovascular disease, but is contraindicated in renal dysfunction due to the risk of hyperkalemia. It is not known if patients with end-stage renal disease (ESRD) on hemodialysis are at the same risk for
Natalie A Christy et al.
The Annals of pharmacotherapy, 39(9), 1517-1521 (2005-08-04)
To evaluate the level of evidence for treatment of hirsutism associated with polycystic ovary syndrome (PCOS) with spironolactone. Studies and reports were located in MEDLINE (1966-January 2005), EMBASE, and International Pharmaceutical Abstracts through the second week of January 2005. Hirsutism
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico